| [1] |
SIEGEL RL, MILLER KD, JEMAL A. Cancer statistics, 2020[J]. CA Cancer J Clin, 2020, 70(1): 7-30. DOI: 10.3322/caac.21590 |
| [2] |
LI X, GAO ZF, YAN J. Value of tumor markers in the diagnosis of early-stage primary liver cancer and related research advances[J/CD]. Electronic J Liver Tumor, 2014, 1(3): 41-45.(in Chinese)
李汛, 高增法, 严俊. 肿瘤标志物对早期原发性肝癌的诊断价值与研究进展[J/CD]. 肝癌电子杂志, 2014, 1(3): 41-45.
|
| [3] |
MCGLYNN KA, PETRICK JL, EL-SERAG HB. Epidemiology of hepatocellular carcinoma[J]. Hepatology, 2020.[Epub ahead of print]
|
| [4] |
HA M, KIM VN. Regulation of microRNA biogenesis[J]. Nat Rev Mol Cell Biol, 2014, 15(8): 509-524. DOI: 10.1038/nrm3838 |
| [5] |
KOZOMARA A, BIRGAOANU M, GRIFFITHS-JONES S. miRBase: From microRNA sequences to function[J]. Nucleic Acids Res, 2019, 47(D1): d155-d162. DOI: 10.1093/nar/gky1141 |
| [6] |
VICKERS KC, PALMISANO BT, SHOUCRI BM, et al. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins[J]. Nat Cell Biol, 2011, 13(4): 423-433. DOI: 10.1038/ncb2210 |
| [7] |
GEEKIYANAGE H, RAYATPISHEH S, WOHLSCHLEGEL JA, et al. Extracellular microRNAs in human circulation are associated with miRISC complexes that are accessible to anti-AGO2 antibody and can bind target mimic oligonucleotides[J]. Proc Natl Acad Sci U S A, 2020, 117(39): 24213-24223. DOI: 10.1073/pnas.2008323117 |
| [8] |
HAND NJ, MASTER ZR, LE LAY J, et al. Hepatic function is preserved in the absence of mature microRNAs[J]. Hepatology, 2009, 49(2): 618-626. DOI: 10.1002/hep.22656 |
| [9] |
SEKINE S, OGAWA R, ITO R, et al. Disruption of Dicer1 induces dysregulated fetal gene expression and promotes hepatocarcinogenesis[J]. Gastroenterology, 2009, 136(7): 2304-2315. DOI: 10.1053/j.gastro.2009.02.067 |
| [10] |
JIANG M, GONG X, XIAO XQ, et al. Expression of serum miRNA-122-3p in patients with CHB treated with PEG-interferon-alpha 2b[J]. Int J Virol, 2019, 26(5): 293-298.(in Chinese) DOI: 10.3760/cma.j.issn.1673-4092.2019.05.002 |
| [11] |
BANDIERA S, PFEFFER S, BAUMERT TF, et al. miR-122-a key factor and therapeutic target in liver disease[J]. J Hepatol, 2015, 62(2): 448-457. DOI: 10.1016/j.jhep.2014.10.004 |
| [12] |
XUE X, ZHAO NY, YU HT, et al. Discovery of novel inhibitors disrupting HIF-1α/von Hippel-Lindau interaction through shape-based screening and cascade docking[J]. PeerJ, 2016, 4: e2757. DOI: 10.7717/peerj.2757 |
| [13] |
LI M, TANG Y, WU L, et al. The hepatocyte-specific HNF4α/miR-122 pathway contributes to iron overload-mediated hepatic inflammation[J]. Blood, 2017, 130(8): 1041-1051. DOI: 10.1182/blood-2016-12-755967 |
| [14] |
SHAN LQ, FANG Z, LIU H, et al.Mechanism of miR-92a in promoting proliferation and migration of hepatoma cells by down-regulating expression of RAB3B[J]. J Clin Exp Med, 2019, 18(12): 1266-1270.(in Chinese) DOI: 10.3969/j.issn.1671-4695.2019.12.010 |
| [15] |
MURAKAMI Y, YASUDA T, SAIGO K, et al. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues[J]. Oncogene, 2006, 25(17): 2537-2545. DOI: 10.1038/sj.onc.1209283 |
| [16] |
JIANG J, GUSEV Y, ADERCA I, et al. Association of microRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival[J]. Clin Cancer Res, 2008, 14(2): 419-427. DOI: 10.1158/1078-0432.CCR-07-0523 |
| [17] |
PARK JK, KOGURE T, NUOVO GJ, et al. miR-221 silencing blocks hepatocellular carcinoma and promotes survival[J]. Cancer Res, 2011, 71(24): 7608-7616. DOI: 10.1158/0008-5472.CAN-11-1144 |
| [18] |
LI H, XIANG Z, LIU Y, et al. MicroRNA-133b inhibits proliferation, cellular migration, and invasion via targeting LASP1 in hepatocarcinoma cells[J]. Oncol Res, 2017, 25(8): 1269-1282. DOI: 10.3727/096504017X14850151453092 |
| [19] |
XIAN Y, WANG L, YAO B, et al. MicroRNA-769-5p contributes to the proliferation, migration and invasion of hepatocellular carcinoma cells by attenuating RYBP[J]. Biomed Pharmacother, 2019, 118: 109343. DOI: 10.1016/j.biopha.2019.109343 |
| [20] |
WU JY, LAI ZD, TIAN YF, et al. Expression and clinical significance of serum exosomal microRNA-221-3p in hepatocellular carcinoma[J]. J Clin Hepatol, 2020, 36(8): 1768-1772. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2020.08.018 |
| [21] |
WONG CC, AU SL, TSE AP, et al. Switching of pyruvate kinase isoform L to M2 promotes metabolic reprogramming in hepatocarcinogenesis[J]. PLoS One, 2014, 9(12): e115036. DOI: 10.1371/journal.pone.0115036 |
| [22] |
FORNARI F, GRAMANTIERI L, GIOVANNINI C, et al. MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells[J]. Cancer Res, 2009, 69(14): 5761-5767. DOI: 10.1158/0008-5472.CAN-08-4797 |
| [23] |
WANG SC, LIN XL, LI J, et al. MicroRNA-122 triggers mesenchymal-epithelial transition and suppresses hepatocellular carcinoma cell motility and invasion by targeting RhoA[J]. PLoS One, 2014, 9(7): e101330. DOI: 10.1371/journal.pone.0101330 |
| [24] |
GUO W, QIU Z, WANG Z, et al. MiR-199a-5p is negatively associated with malignancies and regulates glycolysis and lactate production by targeting hexokinase 2 in liver cancer[J]. Hepatology, 2015, 62(4): 1132-1144. DOI: 10.1002/hep.27929 |
| [25] |
ZHANG LF, LOU JT, LU MH, et al. Suppression of miR-199a maturation by HuR is crucial for hypoxia-induced glycolytic switch in hepatocellular carcinoma[J]. EMBO J, 2015, 34(21): 2671-2685. DOI: 10.15252/embj.201591803 |
| [26] |
FORNARI F, MILAZZO M, CHIECO P, et al. MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells[J]. Cancer Res, 2010, 70(12): 5184-5193. DOI: 10.1158/0008-5472.CAN-10-0145 |
| [27] |
HOU J, LIN L, ZHOU W, et al. Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma[J]. Cancer Cell, 2011, 19(2): 232-243. DOI: 10.1016/j.ccr.2011.01.001 |
| [28] |
LIU Z, LI W, PANG Y, et al. SF3B4 is regulated by microRNA-133b and promotes cell proliferation and metastasis in hepatocellular carcinoma[J]. EBioMedicine, 2018, 38: 57-68. DOI: 10.1016/j.ebiom.2018.10.067 |
| [29] |
FORNARI F, GRAMANTIERI L, FERRACIN M, et al. MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma[J]. Oncogene, 2008, 27(43): 5651-5661. DOI: 10.1038/onc.2008.178 |
| [30] |
PINEAU P, VOLINIA S, MCJUNKIN K, et al. miR-221 overexpression contributes to liver tumorigenesis[J]. Proc Natl Acad Sci U S A, 2010, 107(1): 264-269. DOI: 10.1073/pnas.0907904107 |
| [31] |
GRAMANTIERI L, FORNARI F, FERRACIN M, et al. MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality[J]. Clin Cancer Res, 2009, 15(16): 5073-5081. DOI: 10.1158/1078-0432.CCR-09-0092 |
| [32] |
FORNARI F, POLLUTRI D, PATRIZI C, et al. In hepatocellular carcinoma miR-221 modulates sorafenib resistance through inhibition of Caspase-3-mediated apoptosis[J]. Clin Cancer Res, 2017, 23(14): 3953-3965. DOI: 10.1158/1078-0432.CCR-16-1464 |
| [33] |
LI LM, HU ZB, ZHOU ZX, et al. Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma[J]. Cancer Res, 2010, 70(23): 9798-9807. DOI: 10.1158/0008-5472.CAN-10-1001 |
| [34] |
ZHOU J, YU L, GAO X, et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma[J]. J Clin Oncol, 2011, 29(36): 4781-4788. DOI: 10.1200/JCO.2011.38.2697 |
| [35] |
LIN XJ, CHONG Y, GUO ZW, et al. A serum microRNA classifier for early detection of hepatocellular carcinoma: A multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study[J]. Lancet Oncol, 2015, 16(7): 804-815. DOI: 10.1016/S1470-2045(15)00048-0 |
| [36] |
EL-ABD NE, FAWZY NA, EL-SHEIKH SM, et al. Circulating miRNA-122, miRNA-199a, and miRNA-16 as biomarkers for early detection of hepatocellular carcinoma in egyptian patients with chronic hepatitis C virus infection[J]. Mol Diagn Ther, 2015, 19(4): 213-220. DOI: 10.1007/s40291-015-0148-1 |
| [37] |
NOMAIR AM, ISSA NM, MADKOUR MA, et al. The clinical significance of serum miRNA-224 expression in hepatocellular carcinoma[J]. Clin Exp Hepatol, 2020, 6(1): 20-27. DOI: 10.5114/ceh.2020.93052 |
| [38] |
de RIE D, ABUGESSAISA I, ALAM T, et al. An integrated expression atlas of miRNAs and their promoters in human and mouse[J]. Nat Biotechnol, 2017, 35(9): 872-878. DOI: 10.1038/nbt.3947 |
| [39] |
DA FONSECA B, DOMINGUES DS, PASCHOAL AR. mirtronDB: A mirtron knowledge base[J]. Bioinformatics, 2019, 35(19): 3873-3874. DOI: 10.1093/bioinformatics/btz153 |
| [40] |
LIU M, ROTH A, YU M, et al. The IGF2 intronic miR-483 selectively enhances transcription from IGF2 fetal promoters and enhances tumorigenesis[J]. Genes Dev, 2013, 27(23): 2543-2548. DOI: 10.1101/gad.224170.113 |
| [41] |
SHANG R, BAEK SC, KIM K, et al. Genomic clustering facilitates nuclear processing of suboptimal pri-miRNA loci[J]. Mol Cell, 2020, 78(2): 303-316. DOI: 10.1016/j.molcel.2020.02.009 |
| [42] |
CANTINI L, BERTOLI G, CAVA C, et al. Identification of microRNA clusters cooperatively acting on epithelial to mesenchymal transition in triple negative breast cancer[J]. Nucleic Acids Res, 2019, 47(5): 2205-2215. DOI: 10.1093/nar/gkz016 |
| [43] |
WU J, DONG T, CHEN T, et al. Hepatic exosome-derived miR-130a-3p attenuates glucose intolerance via suppressing PHLPP2 gene in adipocyte[J]. Metabolism, 2020, 103: 154006. DOI: 10.1016/j.metabol.2019.154006 |
| [44] |
DING J, XU Z, ZHANG Y, et al. Exosome-mediated miR-222 transferring: An insight into NF-κB-mediated breast cancer metastasis[J]. Exp Cell Res, 2018, 369(1): 129-138. DOI: 10.1016/j.yexcr.2018.05.014 |
| [45] |
WEBER JA, BAXTER DH, ZHANG S, et al. The microRNA spectrum in 12 body fluids[J]. Clin Chem, 2010, 56(11): 1733-1741. DOI: 10.1373/clinchem.2010.147405 |
| [46] |
HEEGAARD NH, SCHETTER AJ, WELSH JA, et al. Circulating micro-RNA expression profiles in early stage nonsmall cell lung cancer[J]. Int J Cancer, 2012, 130(6): 1378-1386. DOI: 10.1002/ijc.26153 |
| [47] |
HENEGHAN HM, MILLER N, LOWERY AJ, et al. Circulating microRNAs as novel minimally invasive biomarkers for breast cancer[J]. Ann Surg, 2010, 251(3): 499-505. DOI: 10.1097/SLA.0b013e3181cc939f |
| [48] |
KROH EM, PARKIN RK, MITCHELL PS, et al. Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR)[J]. Methods, 2010, 50(4): 298-301. DOI: 10.1016/j.ymeth.2010.01.032 |
| [49] |
XU J, WU C, CHE X, et al. Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis[J]. Mol Carcinog, 2011, 50(2): 136-142. DOI: 10.1002/mc.20712 |
| [50] |
PELTIER HJ, LATHAM GJ. Normalization of microRNA expression levels in quantitative RT-PCR assays: Identification of suitable reference RNA targets in normal and cancerous human solid tissues[J]. RNA, 2008, 14(5): 844-852. DOI: 10.1261/rna.939908 |
| [51] |
WANG R, ZHU X, XING Y, et al. Multitag-regulated cascade reaction: A generalizable ultrasensitive microRNA biosensing approach for cancer prognosis[J]. ACS Appl Mater Interfaces, 2019, 11(40): 36444-36448. DOI: 10.1021/acsami.9b14452 |
| [52] |
QIU X, HILDEBRANDT N. Rapid and multiplexed microRNA diagnostic assay using quantum dot-based förster resonance energy transfer[J]. ACS Nano, 2015, 9(8): 8449-8457. DOI: 10.1021/acsnano.5b03364 |
| [53] |
GIRAY BG, EMEKDAS G, TEZCAN S, et al. Profiles of serum microRNAs; miR-125b-5p and miR223-3p serve as novel biomarkers for HBV-positive hepatocellular carcinoma[J]. Mol Biol Rep, 2014, 41(7): 4513-4519. DOI: 10.1007/s11033-014-3322-3 |
DownLoad: